Effectiveness of Wegovy
In one study with 1961 patients taking 2.4mg semaglutide, the mean weight loss achieved was 14.1% by week 68, compared to 2.4% in the placebo group. The results found:
- 86.4% of participants achieved 5% or more weight loss
- 69.1% of participants achieved 10% or more weight loss
- 50.5% of participants achieved 15% or more weight loss
These findings were similar to another study with 175 patients with overweight or obesity. The mean weight loss achieved by week 26 was 10.9% (around 12.3kg). The findings included:
- 87.3% achieved a weight loss of 5%
- 54.9% achieved a weight loss of 10%,
- 23.5% achieved a weight loss of 15%
- 7.8% achieved a weight loss of 20% or more.
The study also highlighted that higher doses (1.7mg and 2.4mg) resulted in more weight loss than the lower doses (0.25mg, 0.5mg, 1mg). Participants on the higher dose achieved a mean weight loss of 12.1% compared to 9.2% for those receiving lower doses. Other benefits included better cardiovascular health, improvement in blood sugar and reduced risk of kidney disease.
The new 7.2mg dose (STEP UP trial)
For patients who plateau on the standard 2.4mg dose, the 7.2mg dose offers extra weight loss support. In the 72-week STEP UP trial, patients taking 7.2mg achieved an average weight loss of around 20.7% to 21%, with nearly half of participants losing 20% or more of their starting body weight. This brings Wegovy’s top-end efficacy virtually neck-and-neck with Mounjaro’s maximum 15mg dose.
However, stopping treatment with semaglutide often led to weight gain. In a study, 327 patients lost an average of 17.3% of their body weight over 68 weeks, but by week 120, they regained an average of 11.6% of that weight. This shows the importance of continued treatment and adhering to lifestyle changes.
Effectiveness of Mounjaro
In a study with 2539 participants, the mean weight loss achieved by week 72 using Mounjaro was:
- 15.0% with 5mg
- 19.5% with 10mg
- 20.9% with 15mg
- 3.1% with placebo
Aside from the weight loss benefits, participants using tirzepatide showed improvements in blood pressure, insulin sensitivity, and cholesterol levels. Additionally, by week 72, most pre-diabetic participants (95%) had normal blood sugar levels.
As previously mentioned, the clinician may recommend staying on a 10mg maintenance dose instead of 15mg due to similar effectiveness and cost benefits. The results prove there’s little difference in weight loss achieved with 10mg compared to 15mg.
Similar to semaglutide, stopping tirzepatide commonly led to weight regain. A study of 670 participants who achieved an average weight reduction of 20.9% by week 36. Half of these individuals continued treatment, while the other half received a placebo. Upon follow-up at week 88, patients who continued taking tirzepatide lost an additional 5.5%, whereas those receiving the placebo experienced a 14% weight gain.
How does Wegovy compare with Mounjaro?
A comparative study found tirzepatide (Mounjaro) to be more effective than semaglutide (Wegovy) in a trial consisting of 41,222 participants. Of these, 32,029 were treated with semaglutide, while 9,193 received tirzepatide. The mean weight loss achieved with each treatment was as follows:
- After 3 months: 5.9% for tirzepatide compared to 3.6% for semaglutide.
- After 6 months: 10.1% for tirzepatide compared to 5.8% for semaglutide.
- After 12 months: 15.3% for tirzepatide compared to 8.3% for semaglutide.
At entry and intermediate maintenance doses, Mounjaro generally leads to faster and greater weight loss due to its dual GLP-1/GIP action. But at their highest respective doses (Wegovy 7.2mg vs Mounjaro 15mg), both treatments deliver comparable results of around 21% average body weight loss.


















